In subgroup analysis, including variables such as histological subtype (adenocarcinoma and SCC), treatment type (pembrolizumab and ipilimumab plus nivolumab), and TP53 mutation status, patients with PD-L1 expression > 50% showed significant differences in both OS and PFS when treated with chemo-immunotherapy. The gene discussed is CD274; the disease is adenocarcinoma.